JAK抑制剂的选择性、疗效与安全性:不断演变的新证据
本文综述了泛JAK抑制剂与选择性JAK抑制剂在炎症性疾病中的证据,涵盖类风湿关节炎、银屑病/银屑病关节炎、炎症性肠病、特应性皮炎和脊柱关节炎等适应症,并总结了新发现的不良反应及包括COVID-19在内的新适应症的最新见解。
要点
- 抑制JAK-STAT信号通路可同时阻断多种细胞因子,为炎症性疾病提供新治疗范式。
- 第二代选择性JAK抑制剂旨在提高选择性并可能降低副作用风险。
- 多种JAK抑制剂已获批用于不同疾病,更多药物正在研究新适应症。
核心结论
- 通过抑制多种细胞因子共用的JAK-STAT信号通路,JAK抑制剂为炎症性疾病治疗创造了新范式。
- 第二代选择性JAK抑制剂旨在实现更高的选择性并可能降低副作用风险。
- 多种药物已获批用于不同疾病,更多药物正在针对多个新适应症进行研究。
研究设计与样本
- 本文为综述,总结了泛JAK抑制剂与选择性JAK抑制剂的现有证据以及关于新副作用和适应症的最新见解。
主要发现
- 疾病相关免疫反应通常涉及多种细胞因子的复杂相互作用,因此阻断单一细胞因子不一定能使所有炎症性疾病患者获得持续缓解。
- 通过抑制细胞因子家族共用的JAK-STAT信号通路,JAK抑制剂为炎症性疾病治疗创造了新范式。
- 多种JAK抑制剂已获批用于不同疾病,更多药物正在针对多个新适应症进行研究。
- 第二代选择性JAK抑制剂旨在实现更高的选择性并可能降低副作用风险。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fundamental insight gained over the last decades led to the discovery of cytokines as pivotal drivers of inflammatory diseases such as rheumatoid arthritis, psoriasis/psoriasis arthritis, inflammatory bowel diseases, atopic dermatitis and spondylarthritis. A deeper understanding of the pro-inflammatory and anti-inflammatory effects of various cytokines has prompted new cytokine-targeting therapies, which revolutionised the treatment options in the last years for patients with inflammatory disorders. Disease-associated immune responses typically involve a complex interplay of multiple cytokines. Therefore, blockade of one single cytokine does not necessarily lead to a persistent remission in all patients with inflammatory disorders and fostered new therapeutic strategies targeting intracellular pathways shared by multiple cytokines. By inhibiting JAK-STAT signalling pathways common to families of cytokines, JAK-inhibitors (JAKinibs) have created a new paradigm for the treatment of inflammatory diseases. Multiple agents have been approved for various disorders and more are being investigated for several new indications. Second-generation selective JAKinibs have been devised with the aim to achieve an increased selectivity and a possible reduced risk of side effects. In the current review, we will summarise the current body of evidence of pan versus selective JAKinibs and the most recent insights on new side effects and indications, including COVID-19.
引用
- Bonelli M, Kerschbaumer A, Kastrati K, et al. Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story. Ann Rheum Dis. 2024. PMID: 37923366. doi:10.1136/ard-2023-223850
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。